A Randomised, Open-label, 4-way Crossover Study to Characterize the Pharmacokinetics, Safety and Efficacy of FDC Tiotropium/Salmeterol, Tiotropium, Salmeterol and a Free Combination of Tiotropium Plus Salmeterol Following 4-week Treatment Periods in Patients With COPD.
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2014
At a glance
- Drugs Tiotropium bromide (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Planned number of patients changed from 51 to 50 as reported by ClinicalTrials.gov.
- 04 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov